Zevra Therapeutics, Inc. (ZVRA)

NASDAQ • Healthcare

$9.81

-$0.51 (-5.0%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$10.25

Day Range$9.76 - $10.25

Avg. Volume (3M)874.6K

Market Cap$582.5M

P/E Ratio10.2

52 Week Range

$8.01$15.04

Next EarningsIn 9 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$39.6M100%

Gross Profitminus cost of goods$38.1M96%

Operating Incomeminus R&D and overhead$16.7M42%

Net Incomeminus taxes and the rest$8.7M22%

In plain terms: out of every $100 in revenue, Zevra Therapeutics, Inc. keeps $22 as net profit.

Fundamentals & Financials

Revenue (TTM)

$136M

Net Income (TTM)

$58.2M

EPS (TTM)

$0.96

ROA (TTM)

19.25%

Current Ratio

5.17

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-44.7%Q3 2025$1.21

+50.0%Q4 2025-$0.01

+316.7%Q1 2026$0.21

+900.0%Q2 2026$0.6

+27.3%Q3 2026$0.14

Nov 3

in 9 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Zevra Therapeutics, Inc. (ZVRA) is set to report earnings on November 4, 2026. Wall Street is looking for consensus EPS of $0.14 on consensus revenue of $37.1 million. For trailing context, revenue increased +53.3% year over year last quarter. Zevra has beaten EPS in 5 of 8 most recent quarters.

View full earnings history

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on medicines for rare diseases and other serious medical conditions. In FY2025, it generated $106.5 million in revenue from a portfolio that includes marketed therapies and development-stage central nervous system programs serving the United States.

Name

Zevra Therapeutics, Inc.

CEO

Neil F. McFarlane

Website

zevra.com

Industry

Healthcare

Year Founded

2006

Employees

Today's Snapshot

AI-generated

ZVRA closed 5% below yesterday's close, in line with a weaker sector. Trading was busier than usual, with volume about half as much again as its usual level. ZVRA is due to report earnings on 3 November.

Trading Volume

Above 10d avg 658.7K

987.4K

vs S&P 500 Today

Strong Underperformance

-4.51%

Updated: October 23, 2026 at 20:24 UTC

Technical Indicators

0 Buy2 Neutral6 Sell

ZVRA is under technical pressure with price beneath short- and medium-term averages and key pivot levels, and momentum indicators such as CCI and MACD tilting negative. The ADX is low, implying the downtrend lacks strong directional force, yet downside bias persists as RSI and price structure remain weak and OBV reflects selling. Volatility is moderate, so moves may be measured rather than explosive, and the pivot sits above current levels as nearby resistance. Technical takeaway: Strong Sell.

All signals